Pancreatic Cancer Research

ResearcherHangzhou City UniversityActive in the last 2 years

Zejun Wang

ORCID-verified (high confidence)As of 13 November 2026

Matched on ORCID iD 0000-0003-0313-5819; OpenAlex author ID A5052732719.

Their work

Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.

Pancreatic cancer papers
2 (first author 0, last author 1)
Pancreatic cancer trials
0
Pancreatic cancer grants
0
Collaborators
3
Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 2

  1. Vortioxetine enhances the anti-pancreatic cancer efficacy of gemcitabine through reducing MAOB expression. Last author DOI 10.3389/fphar.2026.1856439↗
  2. The Role of Signaling Pathways in Pancreatic Cancer Targeted Therapy. Co-author DOI 10.1097/coc.0000000000000979↗

Closest collaborators

The 3 strongest of 3 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

  1. Mengjie Gu · 1 shared paper, 2026
  2. Fangfang Zhuo · 1 shared paper, 2023
  3. Jianwei Xu · 1 shared paper, 2023

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.